Literature DB >> 23002445

Elevated interleukin 8 and T-helper 1 and T-helper 17 cytokine levels prior to antiretroviral therapy in participants who developed immune reconstitution inflammatory syndrome during ACTG A5164.

Philip M Grant1, Lauren Komarow, Michael M Lederman, Savita Pahwa, Andrew R Zolopa, Janet Andersen, David M Asmuth, Sridevi Devaraj, Richard B Pollard, Aaron Richterman, Sudheesh Kanthikeel, Irini Sereti.   

Abstract

BACKGROUND: Immune reconstitution inflammatory syndrome (IRIS) reflects an aberrant immune response that can develop in human immunodeficiency virus-infected patients initiating antiretroviral therapy (ART). Its pathogenesis remains unclear.
METHODS: We performed a nested case-control study using specimens from ACTG A5164. We compared plasma biomarkers and T-cell subsets in 19 IRIS and 39 control participants at study entry, ART initiation, and IRIS and used conditional logistic regression to develop IRIS predictive models. We evaluated the effect of corticosteroids on biomarker levels.
RESULTS: Eleven and 8 participants developed paradoxical and unmasking IRIS, respectively, none while still receiving corticosteroids. Compared to controls, cases displayed elevations at study entry in interleukin (IL) 8, T-helper (Th) 1 (IL-2, interferon [IFN]-γ, tumor necrosis factor [TNF]) and Th17 (IL-17) cytokine levels that persisted through ART initiation and IRIS. In logistic regression, baseline higher IFN-γ and TNF were strong predictors of IRIS. Participants who received corticosteroids and later developed IRIS had marked increases in IL-6, IL-8, and IFN-γ at the time of IRIS. T-cell activation markers did not differ in cases and controls prior to ART but were increased in cases at the time of IRIS.
CONCLUSIONS: Increased IL-8, Th1, and Th17 cytokine levels in IRIS patients precede ART initiation and could help identify patient populations at higher risk for IRIS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23002445      PMCID: PMC3488199          DOI: 10.1093/infdis/jis604

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Natural killer cell degranulation capacity predicts early onset of the immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients with tuberculosis.

Authors:  Polidy Pean; Eric Nerrienet; Yoann Madec; Laurence Borand; Didier Laureillard; Marcelo Fernandez; Olivier Marcy; Chan Sarin; Kerya Phon; Sylvia Taylor; Gianfranco Pancino; Françoise Barré-Sinoussi; Daniel Scott-Algara
Journal:  Blood       Date:  2012-02-17       Impact factor: 22.113

2.  Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients.

Authors:  N A Foudraine; E Hovenkamp; D W Notermans; P L Meenhorst; M R Klein; J M Lange; F Miedema; P Reiss
Journal:  AIDS       Date:  1999-02-04       Impact factor: 4.177

3.  Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy.

Authors:  S F Stone; P Price; J Brochier; M A French
Journal:  J Infect Dis       Date:  2001-09-13       Impact factor: 5.226

4.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease.

Authors:  E M Race; J Adelson-Mitty; G R Kriegel; T F Barlam; K A Reimann; N L Letvin; A J Japour
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

5.  Circulating inflammatory biomarkers can predict and characterize tuberculosis-associated immune reconstitution inflammatory syndrome.

Authors:  Lewis J Haddow; Oliver Dibben; Mohamed-Yunus S Moosa; Persephone Borrow; Philippa J Easterbrook
Journal:  AIDS       Date:  2011-06-01       Impact factor: 4.177

6.  Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.

Authors:  Yasunori Okada; Makoto Shinohara; Tomio Kobayashi; Yoshinari Inoue; Takeshi Tomomasa; Tohru Kobayashi; Akihiro Morikawa
Journal:  J Pediatr       Date:  2003-09       Impact factor: 4.406

7.  Determinants of immune reconstitution inflammatory syndrome in HIV type 1-infected patients with tuberculosis after initiation of antiretroviral therapy.

Authors:  Guillaume Breton; Xavier Duval; Candice Estellat; Xavier Poaletti; Daniel Bonnet; David Mvondo Mvondo; Pascale Longuet; Catherine Leport; Jean-Louis Vildé
Journal:  Clin Infect Dis       Date:  2004-11-09       Impact factor: 9.079

8.  Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.

Authors:  R I Scheinman; P C Cogswell; A K Lofquist; A S Baldwin
Journal:  Science       Date:  1995-10-13       Impact factor: 47.728

9.  Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome.

Authors:  Graeme Meintjes; Keira H Skolimowska; Katalin A Wilkinson; Kerryn Matthews; Rebecca Tadokera; Anali Conesa-Botella; Ronnett Seldon; Molebogeng X Rangaka; Kevin Rebe; Dominique J Pepper; Chelsea Morroni; Robert Colebunders; Gary Maartens; Robert J Wilkinson
Journal:  Am J Respir Crit Care Med       Date:  2012-06-14       Impact factor: 21.405

10.  Resumption of HIV replication is associated with monocyte/macrophage derived cytokine and chemokine changes: results from a large international clinical trial.

Authors:  Alessandro Cozzi-Lepri; Martyn A French; John Baxter; Pablo Okhuysen; Montserrat Plana; Jacqueline Neuhaus; Alan Landay
Journal:  AIDS       Date:  2011-06-01       Impact factor: 4.177

View more
  33 in total

Review 1.  HIV infection and immune activation: the role of coinfections.

Authors:  Afroditi Boulougoura; Irini Sereti
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

2.  Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.

Authors:  Tory P Johnson; Karan Patel; Kory R Johnson; Dragan Maric; Peter A Calabresi; Rodrigo Hasbun; Avindra Nath
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

3.  Immunological profiling of tuberculosis-associated immune reconstitution inflammatory syndrome and non-immune reconstitution inflammatory syndrome death in HIV-infected adults with pulmonary tuberculosis starting antiretroviral therapy: a prospective observational cohort study.

Authors:  Shruthi Ravimohan; Neo Tamuhla; Andrew P Steenhoff; Rona Letlhogile; Kebatshabile Nfanyana; Scarlett L Bellamy; Rob Roy MacGregor; Robert Gross; Drew Weissman; Gregory P Bisson
Journal:  Lancet Infect Dis       Date:  2015-02-09       Impact factor: 25.071

4.  Clinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.

Authors:  Philip M Grant; Lauren Komarow; Alejandro Sanchez; Fred R Sattler; David M Asmuth; Richard B Pollard; Andrew R Zolopa
Journal:  HIV Clin Trials       Date:  2014 Jul-Aug

5.  Role of IL-6 in Mycobacterium avium--associated immune reconstitution inflammatory syndrome.

Authors:  Daniel L Barber; Bruno B Andrade; Cortez McBerry; Irini Sereti; Alan Sher
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

6.  Dectin immunoadhesins and pneumocystis pneumonia.

Authors:  David M Ricks; Kong Chen; Mingquan Zheng; Chad Steele; Jay K Kolls
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

7.  Emergence of Polyfunctional Cytotoxic CD4+ T Cells in Mycobacterium avium Immune Reconstitution Inflammatory Syndrome in Human Immunodeficiency Virus-Infected Patients.

Authors:  Denise C Hsu; Kimberly F Breglio; Luxin Pei; Chun-Shu Wong; Bruno B Andrade; Virginia Sheikh; Margery Smelkinson; Constantinos Petrovas; Adam Rupert; Leonardo Gil-Santana; Adrian Zelazny; Steven M Holland; Kenneth Olivier; Daniel Barber; Irini Sereti
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

Review 8.  The immunopathogenesis of cryptococcal immune reconstitution inflammatory syndrome: understanding a conundrum.

Authors:  David B Meya; Yukari C Manabe; David R Boulware; Edward N Janoff
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

Review 9.  Immune restoration after antiretroviral therapy: the pitfalls of hasty or incomplete repairs.

Authors:  Eleanor M P Wilson; Irini Sereti
Journal:  Immunol Rev       Date:  2013-07       Impact factor: 12.988

10.  A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of a Chemokine Receptor 5 (CCR5) Antagonist to Decrease the Occurrence of Immune Reconstitution Inflammatory Syndrome in HIV-Infection: The CADIRIS Study.

Authors:  Juan G Sierra-Madero; Susan Ellenberg; Mohammed S Rassool; Ann Tierney; Pablo F Belaunzarán-Zamudio; Alondra López-Martínez; Alicia Piñeirúa-Menéndez; Luis J Montaner; Livio Azzoni; César Rivera Benítez; Irini Sereti; Jaime Andrade-Villanueva; Juan L Mosqueda-Gómez; Benigno Rodriguez; Ian Sanne; Michael M Lederman
Journal:  Lancet HIV       Date:  2014-11-01       Impact factor: 12.767

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.